Post Trial Access Program of TAK-577 for Von Willebrand Disease (VWD)
ConditionVon Willebrand Disease (VWD)
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
AgeNot listed
SponsorTakeda
About this trial
The post-trial access program allows eligible participants to gain access to unlicensed treatment on compassionate grounds. Recombinant von Willebrand factor (rVWF) also known as TAK-577, is a medicine to help treat Von Willebrand Disease (VWD). This post-trial access program enables continued access to children and adults who are benefitting from treatment on study SHP677-304 (NCT03879135) study.
Eligibility criteria
Qualifiers
Participant has completed the treatment period of the SHP677-304 study (at least 12 months on study treatment).
Participant had good clinical response to rVWF treatment.
Participant does not have access to any comparable or satisfactory alternative replacement therapy available at country level.
Participant will be/has been negatively impacted by discontinuation of rVWF.
Disqualifiers
None
Trial design
Treatments tested in this trial
- TAK-577
Treatment groups
No treatment groups listed
Locations
Sponsors and collaborators
Source ClinicalTrials.gov